Sara Secall
Partner& Life Sciences Investment Director @ Inveready
Barcelona, Spain
Sara Secall is a seed investor at Inveready in Barcelona focused on Biotechnology and Health Care. Sara is responsible for building the Biotech Portfolio. Sara has an extensive international career in technology investing. She was involved in investing and exiting several Venture Capital investments while working for Chevron Technology Ventures, the corporate Venture Capital group based in California with USD 210 MM under management. Prior tojoining Inveready, as Director of Spin Outs for the University of Barcelona, she was involved in starting and financing over 25 technology start ups and she negotiated numerous technology licenses, mainly in the biotechnology sector. She has worked extensively in the USA, Latin America and Europe.Sara holds a BS in Chemistry, MSc from Indiana University and an MBA from the London Business School.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Sara Secall invests in
Stages Sara Secall invests in
Countries Sara Secall invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (67%)
- Health Care 4 (44%)
- Pharmaceutical 4 (44%)
- Medical 3 (33%)
- Biopharma 1 (11%)
Stage
- Seed 3 (33%)
- Venture - Series Unknown 3 (33%)
- Series A 1 (11%)
- Series B 1 (11%)
- Funding Round 1 (11%)
Country
- Spain 6 (67%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Connecta Therapeutics
|
Connecta Therapeutics is a biotechnology company that develops new treatments for unresolved medical needs of the central nervous system. It focuses on the development of a first-in-class drug for the treatment of fragile X syndrome. | $4.2M / Venture - Series Unknown / Sep 10, 2026 | |
Iteria Biopharma
|
Iteria Biopharma focused on discovering and developing precision oncology drugs, particularly first-in-class new chemical entities (NCEs) for challenging cancer targets with high unmet medical needs. | $5.9M / Seed / Apr 16, 2026 | |
Ability Pharmaceuticals
|
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs.Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The companydevelops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures.Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization. | $7.7M / Venture - Series Unknown / Mar 11, 2024 | |
|
Innerva Pharmaceuticals
|
Innerva Pharmaceuticals is an ophthalmic pharmaceutical company that is working on developing a new treatment for Ocular Surface Pain. It is dedicated to the research and development of new drugs for the treatment of ocular pain that accompanies various ocular surface diseases, such as dry eye, post-surgical ocular pain and neuropathic ocular pain.. | $2.5M / Oct 31, 2022 | |
|
Innerva Pharmaceuticals
|
Innerva Pharmaceuticals is an ophthalmic pharmaceutical company that is working on developing a new treatment for Ocular Surface Pain. It is dedicated to the research and development of new drugs for the treatment of ocular pain that accompanies various ocular surface diseases, such as dry eye, post-surgical ocular pain and neuropathic ocular pain.. | $2.3M / Seed / Oct 31, 2022 | |
AptaTargets
|
AptaTargets is a biopharmaceutical company focused in developing therapeutic applications based in aptamer technology. AptaTargets drug candidates start at preclinical stages and aims to reach phase 2 of clinical trials | $5.9M / Series B / Oct 14, 2020 | |
Qrem
|
Qrem was founded by Josep M. Escuer and Nuria Noguera in July 2016. They were healthcare technology intra-entrepeneurs in an engineering services multinational company during 7 and 11 years respectively.Today they have a wealth of experience in transforming ideas from clinicians and scientists into profitable and cost-effective products.Regenerative medicine is a game-changing area of medicine with the potential to fully heal damaged tissues and organs.Our vision is that regenerative therapies will be the next revolution in medicine and particularly autologous regenerative therapies (personalized medicine) have shown great promise in treating life-threatening diseases.Our Mission is to drive standardization and scalability of autologous regenerative therapies making available Lab-in-a-box devices to clinicians to carry out the therapies at their offices in an easy and cost-effective way to address the unmet needs of patients around the world. | $1.1M / Seed / Mar 16, 2020 | |
Spiral Therapeutics
|
Spiral Therapeutics develops biopharmaceutical therapies focused on treating inner ear disorders, including hearing loss, balance disorders, and related auditory conditions. The company operates as a clinical-stage drug developer, advancing a pipeline of therapeutics designed to address conditions with limited or no approved treatment options. Itscore approach combines proprietary drug formulations with targeted delivery technologies that enable precise and sustained administration of therapeutics directly to the cochlea. This method is designed to improve treatment effectiveness by delivering drugs to specific areas of the inner ear while minimizing systemic exposure.Spiral Therapeutics focuses on developing small-molecule therapies and sustained-release formulations that address inflammation and other underlying causes of inner ear disorders. Its lead programs include treatments for conditions such as Ménière’s disease, where symptoms like vertigo, tinnitus, and hearing loss are linked to inner ear dysfunction. | $5.6M / Series A / Dec 12, 2018 | |
|
AptaTargets
|
AptaTargets is a biopharmaceutical company focused in developing therapeutic applications based in aptamer technology. AptaTargets drug candidates start at preclinical stages and aims to reach phase 2 of clinical trials | $3M / Venture - Series Unknown / May 17, 2017 |
Co-Investors
About Inveready
Inveready is a Southern Europe leading alternative investor with +2bn€ of assets under management, investing across 35+ funds in Venture Capital, BioTech, Venture Debt, Private Equity, Public Equity, Infrastructure, Fund of Funds, and other. Founded in 2008, Inveready counts on 250+ active companies and 64 exits.Some of our portfolio companieshave been acquired by multinationals such as Intel, Symantec, IBM, and Facebook, whilst others are listed in public markets such as NASDAQ, the Spanish BME Growth, AIM London, and Euronext Growth. (visit www.inveready.com for more information).
Inveready Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ignacio Fonts
Member BOD
|
|||
|
Sara Secall
Partner& Life Sciences Investment Director
|
|||
|
Adanne Branch
Owner
|
|||
Aniol Brosa
Partner
|
|||
Carlos Conti
GP
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sara Secall invest in?
Sara Secall invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Seed and Venture - Series Unknown stage. Most of the 9 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sara Secall?
Public channels for Sara Secall include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sara Secall last invest?
The most recent investment recorded for Sara Secall closed in Sep 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
